Clinical trials: CONTROL Condition
Multiple Sclerosis, NMO Spectrum Disorder
A Study of LP-168 in Healthy Volunteers
This is a Phase I study designed to assess the safety, tolerability and pharmacokinetics of LP-168 in healthy human volunteers.
- Trial name
- NCT05432713
- Testing
- LP-168 tablet
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Medication-Induced Dyskinesia
Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia
This is a double-blind, randomized, placebo-controlled Phase 2a study evaluating the safety, tolerability, and preliminary efficacy of up to 2 mg/day (1 mg BID) of NLX-112 versus placebo in patients with moderate to severe L-DOPA…
- Trial name
- NCT05148884
- Testing
- NLX-112
- Where
- 5 sites in Sweden
- Volunteers
- 27 people
- Sponsor
- Neurolixis SAS
Hypercholesterolemia, LDL Cholesterol
Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins
This study is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of LGT209 in hypercholesterolemic patients taking common statin medications and in healthy volunteers.
- Trial name
- NCT01859455
- Testing
- LGT209 50 mg, LGT209 300 mg, Statins (atorvastatin or simvastatin)
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Diseases [C] - Musculoskeletal Diseases [C05
PRGF-ENDORET® Infiltrations in the Treatment of Low Back Pain.
The goal of this clinical trial is to evaluate the efficacy of PRGF in reducing pain and improving patients' quality of life. Researchers will compare an experimental drug (Plasma Rich in Growth Factors) to a control…
- Trial name
- NCT06715085
- Testing
- Plasma Rich in Growth Factors (PRGF), Corticosteroid solution (Celestone Cronodose suspension for injection) in saline solution.
- Where
- Spain
- Volunteers
- 48 people
- Sponsor
- Biotechnology Institute IMASD
Schizophrenia
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult patients diagnosed with acutely exacerbated schizophrenia.
- Trial name
- NCT06179108
- Testing
- LB-102
- Where
- 25 sites in United States
- Volunteers
- 359 people
- Sponsor
- LB Pharmaceuticals Inc.
Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis)
Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults
Multicenter, phase III, randomized, blinded, controlled, parallel group with safety extension phase with crossover or continued treatment.
- Trial name
- ENLIGHTEN 1 (NCT05219968)
- Testing
- LYR-210, Background Therapy
- Where
- 55 sites in United States, Austria and 3 more
- Volunteers
- 196 people
- Sponsor
- Lyra Therapeutics
Anorexia Nervosa
Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa
The purpose of this study is to determine if administration of RM-131 is effective in improving appetite and gastrointestinal symptoms leading to the recovery of patients with anorexia nervosa in the outpatient setting.
- Trial name
- NCT01642550
- Testing
- RM-131
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Motus Therapeutics, Inc.
Cataract, Lens Opacities
Clinical Study to Evaluate Clinical Outcomes of LuxSmart IOL as Compared With LuxGood IOL
This study is a multicentric, prospective, randomised, controlled, post-market clinical follow up (PMCF) study to investigate safety, visual outcomes and contrast sensitivity after bilateral implantation of either LuxSmart IOLs…
- Trial name
- NCT06105190
- Testing
- Implantation of premium monofocal IOL, LuxSmart (device under investigation), Implantation of monofocal IOL, LuxGood (control device)
- Where
- 8 sites in Austria, Czechia and 4 more
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- Cutting Edge SAS
Cancer
Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists
This study will examine the efficacy and safety of lapatinib in patients with ErbB2 positive ovarian, gastric/esophageal adenocarcinoma, uterine serous papillary, or bladder cancers.
- Trial name
- NCT00447226
- Where
- 20 sites in United States
- Volunteers
- 32 people
- Sponsor
- GlaxoSmithKline
Asthma
A Safety and Efficacy Study of Intranasal GSK2245035 in Adults With Allergic Asthma
GSK2245035 belongs to a novel class of agonist drugs targeted at toll like receptors (TLR). T-helper cell 2 (Th2) driven inflammation is a key patho-physiological mechanism in allergic asthma.
- Trial name
- NCT03707678
- Testing
- GSK2245035, FP-DPI, Albuterol/Salbutamol
- Sponsor
- GlaxoSmithKline
Celiac Disease
Latiglutenase as a Treatment for Celiac Disease
Single Center, Randomized, Double-Blind, Placebo Controlled, Gluten Challenge Trial in Patients with Well-Controlled Celiac Disease
- Trial name
- NCT03585478
- Testing
- Latiglutenase
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Immunogenics, LLC
Amyotrophic Lateral Sclerosis (ALS)
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
- Trial name
- UNITE-ALS (NCT07023835)
- Testing
- 50 mg Usnoflast, 75 mg Usnoflast
- Where
- 49 sites in United States, Australia and 10 more
- Volunteers
- 240 people
- Sponsor
- Zydus Therapeutics Inc.
Overweight and Obesity
Evaluation of Libramed in Obesity Treatment
Randomized, double-blind, placebo-controlled study aimed at evaluating the effects of a 3-months treatment with Policaptil Gel Retard on postprandial incretin hormones release and satiety in obese women
- Trial name
- ELOT (NCT03537235)
- Testing
- Libramed
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- Aboca Spa Societa' Agricola
Inflammation, Inflammatory Response
A Study to Evaluate the Effects of a Marine Lipid Oil Concentrate Formulation on Inflammation
To assess the efficacy and safety of a Marine Lipid Oil Concentrate formulation on inflammatory biomarkers and overall well-being in male and female subjects who are overweight to mildly obese, but otherwise generally healthy.
- Trial name
- NCT04269876
- Testing
- Marine Lipid Oil Concentrate, Dietary Supplement
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Supplement Formulators, Inc.
Knee Osteoarthritis
Comparison of the Efficacy, Tolerability and Safety of actiTENS to Those of Level 2 Analgesic Treatments.
This is a phase 3, multicentre, prospective, single-blind on principal efficacy criterion, 2 parallel groups, randomized, controlled clinical study comparing efficacy and safety of actiTENS versus systemic level 2 analgesics…
- Trial name
- ArthroTENS (NCT03902340)
- Testing
- ActiTENS, Level 2 Analgesic Treatments
- Where
- France
- Volunteers
- 110 people
- Sponsor
- Sublimed
Hypophosphatasia (HPP)
A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1
This is a phase 1/2a randomised, placebo controlled, double-blind study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALE1 on healthy adult subjects and adult patients with Hypophosphatasia…
- Trial name
- NCT07179640
- Testing
- ALE1
- Where
- 3 sites in Germany, New Zealand and 1 more
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Alesta Therapeutics
Systemic Lupus Erythematosus, Healthy
A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus
The purpose of this study is to assess the safety and tolerability of JNJ-55920839 following single ascending intravenous (IV) dose administration in healthy participants and a single subcutaneous dose in healthy participants and…
- Trial name
- NCT02609789
- Testing
- JNJ-55920839
- Where
- 16 sites in United States, Belgium and 5 more
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Open-Angle Glaucoma
Safety and Effectiveness of the Sight Sciences VISCO™360 Versus SLT in Primary Open Angle Glaucoma
The purpose of this study is to evaluate the safety and effectiveness of the Sight Sciences VISCO™360 Viscosurgical System in reducing intraocular pressure (IOP) in adult, pseudophakic subjects with open-angle glaucoma.
- Trial name
- NCT02928289
- Testing
- VISCO360 ab interno canaloplasty surgery, Selective Laser Trabeculoplasty (SLT)
- Where
- 6 sites in United States
- Volunteers
- 29 people
- Sponsor
- Sight Sciences, Inc.
Osteoarthritis, Knee
Autologous Adipose-derived Stromal Vascular Fraction for Treatment of Knee Osteoarthritis
This is a pivotal study to evaluate the efficacy and safety of a single injection of autologous adipose-derived SVF produced using the GID SVF-2 device system for treatment of pain with concomitant improvement in function…
- Trial name
- NCT04440189
- Testing
- GID SVF-2 Device System
- Where
- 9 sites in United States
- Volunteers
- 114 people
- Sponsor
- GID BIO, Inc.
Hypereosinophilic Syndrome
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy.
- Trial name
- DESTINY (NCT05334368)
- Testing
- Depemokimab
- Where
- 60 sites in United States, Argentina and 14 more
- Volunteers
- 110 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.